The key to successful cancer treatment is early diagnosis.
If detected at the early stage, when there are no visible symptoms, cancer can be cured without any complex aggressive therapies.
The average 5-year survival rate of cancer patients after treatment:
Any process in the body reflects in the cell, a structural unit of the body. Buccal cells (cells from the inside of the cheek) are the fastest to respond to any changes.
We have established some regularities in the changes in electrical activity of buccal cells and their cytomorphological parameters in case of any changes in the life processes.
By examining various parameters of cells and their combinations, our system called The Luven Diagnostic allows, with a high degree of accuracy, to detect oncological diseases, localization of a diseased organ, tendency of progression of the disease and comorbidities.
A large number of studies ,conducted in cancer centers ,showed that The Luven methods’ accuracy is up to 96% for some types of cancer, which is a very high rate comparable to biopsy.
High diagnostic accuracy at a low cost;
One examination replaces several types of diagnostic tests;
No pain, discomfort or side effects;
A possibility to check several organs with one test;
Early disease diagnosis when there are still no visible signs of a disease;
Portability (space-saving equipment can be carried around and used in areas with no hospitals or laboratories);
Quick test results (within 15 minutes);
Periodic checkups to avoid non-effective drug therapies;
Diagnosis allows to detect cancer in its early stages, to ascertain a diseased organ and stage of disease, to carry out metastatic evaluation, to differentiate between benign and malignant tumors. This diagnostic method is particularly valuable as it allows to select the most suitable type of treatment, since there are no restrictions for the frequency of testing and no counter-indications. After a course of chemotherapy, this method allows to estimate effectiveness of the treatment given.
Luven recognizes metastatic lesions when other diagnostic methods are helpless;
Unlike other diagnostic methods, it differentiates between chronic inflammatory conditions and cancer. Other diagnostic techniques, including paracentesis with a negative result, are not 100% reliable.
beginning of studies
to run a test
Based on data processing results the report shows:
The development of this method started in early 1983 at the research institute, chair for genetics. Based on the cellular theory by Rudolf Vichow, a team of scientists was working on a diagnostic method and studying buccal cells.
It took 28 years to collect a so-called “deviation album” which established a relationship between cell parameters and body conditions.
Ms. Galina Shchukina, a genetic scientist and cytologist, was at the head of the scientific research. She conducted an in-depth study of scientific papers describing a new biophysical concept of the gene activity regulation based on the role of relationship between homologous chromosomes and genome. Ms. Galina then requested her husband Mr. Alexander Shchukin to search for a technique allowing to accurately count a number of positively and negatively charged nuclei. Since then Mr. Alexander, a nuclear physicist who studied at the chair for experimental nuclear physics, became a part of the team and buckled down to that difficult task. During eight years the lab scientists were trying to find an accurate method to count charged nuclei and get a precise number. As a result of thousands of experiments, they invented an ion trap sending impulses on cells and, thus, allowing to differentiate between positively and negatively charged cell nuclei. In this manner, 8 years later, it became possible to calculate the percentage of negative charged nuclei (bioelectrical charge) and to easily estimate an actual physiological age of any organism
It was the first milestone in the development of LUVEN a unique diagnostic and treatment system.
The Shchukiny family took the lead of the team of scientists continuing further studies and research of this concept. All of this culminated in 2004 when they developed a new diagnostic method the main idea of which is that any changes in the body manifest at the cellular level, including buccal cells.
It has been more than 30 years now since they started comparing changes in healthy and diseased cells and studying interrelation between them. So far, has collected samples for examination from more than twenty thousand patients.
From 2007 until the present day, a new cancer diagnostic method has been formalized and automated by the scientists in cooperation with Mr. Nikolay Shchukin, Ms. Galina and Mr. Alexander’s son and postgraduate student of chair for biochemical engineering.
In 2010 the team embraced IT specialists and mathematicians who put all the knowledge and formulae into the software of Luven Diagnostic system. They set up a commercial enterprise promoting the new technology.
In 2014 they launched Luven Diagnostic franchise which boosted development in many countries (more than 23 newly opened diagnostic rooms diagnosed more than two thousand patients), but soon afterwards our team faced a large number of problems that couldn’t be solved without big financial investment:
1. The software, at that time, transmitted images from the microscope to our processing center where a team of cytologists would specify parameters for the received material, after which the computer would process the data and give a result. We were putting great efforts into teaching cytologists how to correctly record image parameters which closed the door to our prospective growth. Also, our lab assistants couldn’t work 24/7 which caused long delays in text interpretations, just as the number of those tests was constantly increasing;
2. We couldn’t sell our diagnostic system to other countries, since the method required certification and clinical trials which, in turn, requires big money.
Finally, we decided to take a pause and improve the software by adding computer-assisted learning (automatic corrections of coefficients in formulae for the database of clinically confirmed patient diagnoses) that will allow us to constantly improve diagnostic accuracy, run clinical tests and re-start our project in many countries at the same time.
Unlike the majority of projects involving crowdfunding, our company has already completed 90% of the project.
We have already conducted studies, developed the entire procedure and received several patents for the procedure. Also, we have all the necessary equipment and software which can produce income and treat people even today.
Token holders have two opportunities:
*Investors from the countries where tokens equal securities (such as USA or China) will not be able to share the company income, however, they will have a possibility to exchange their tokens for tests with a 80% discount, use them or sell them to wholesale customers. It means that the company will exchange tokens for tests 5 times cheaper than the market price.
The company will start selling sets of necessary equipment to labs, hospitals and physicians in private practice.
Tests will be read on the company servers, each test will be paid for. The diagnosis price will vary from country to country. The lowest price will be based on the current GDP per capita. The company services will cost 50% of the retail price. In this manner, we will ensure a balance between affordability of the diagnosis for the population and Company income.Test price
We are planning to re-invest 50% of the company income back into the business and technology development and allocate another 50% to the token holders.
Development of the cancer diagnostic method started, based on the study of buccal cells(cells from the inside of the cheek)
A cytomorphobiologial diagnostic method appeared which formed the basis of the diagnostic complex
Team expansion. A commercial enterprise promoting the LUVEN trademark was established. The software automating a part of the diagnostic procedure was created.
The diagnostic method was patented, completion of the clinical trials, creation of the software diagnostic complex presented at two international medical exhibitions “The 5th International Medical Forum” and “Health Care 2014”. Opening first franchise outlets.
In five months after launching a franchise, the contracts were signed with more than twenty outlets, half of which have already run tests on more than two thousand patients. Suspension of activities for a time allowing technology enhancement.
Software enhancement, additional clinical trials. Optimizing a big number of the system algorithms.
Preparing and starting a preICO aimed at fundraising for the software enhancement, legal costs and operational expenses of the project.
Start: 12.12.2017 12:00 GMT
Finish: 29.12.2017 12:00 GMT
Start: 15.01.2018 12:00 GMT
Finish: 28.02.2018 12:00 GMT
Further software enhancement, signing contracts with clinics worldwide for conducting clinical trials, opening a research center in Austria. Initiating certification of the method in the European Union and Eurasian Union
Opening 20 new labs in the European Union and Eurasian Union, incorporating a blockchain and developing a domestic exchange for token sale, working on the optical recognition of incoming images of the cell, creating a database of patients and their test results for monitoring tendencies and informing patients on the necessity of being diagnosed
Starting clinical trials and certification in the USA and Asia
Developing home gadgets (a home lab) for running tests on the entire family at any time, launching the product.
At the preICO stage - 3 000 000 tokens (1st day bonus – 30%, 1st week bonus – 25%, 2nd week bonus – 20%, 3d week bonus – 15%)
At the ICO stage - 27 000 000 (1st week – 10%, 1 to 1 onwards)
9,000,000 tokens will be kept by the founders and developers of Luven Diagnostic.
Bonuses will be also awarded for the investment volume
>= 5,000 ETH 5%
>= 3,000 ETH 4%
>= 1,000 ETH 3%
>= 100 ETH 2%
>= 3 ETH 1%
Token standard: ERC20.
Rate: Ethereum = 290 tokens.
Participation in ICO is possible both with Ethereum and Bitcoin.
Start: 12.12.2017 12:00 GMT
Completion: 29.12.2017 12:00 GMT
Start: 15.01.2018 12:00 GMT
Completion: 28.02.2018 12:00 GMT
If all the tokens are sold out at the PREICO stage, ICO will start earlier.
Postgraduate Student of Chair for Biomedical Engineering
Geneticist & Cytologist
Principal Software Engineer
Elena Kovtun. One of our patients.
Tatyana Skrytskaya - PhD in Medical Science, M.D. Board Certified, gynecologic oncologist
If you cannot take part in investing
Please share this page in your social networks
every link or any mentioning about the website and our preICO will help us in achieving our goal and successfully collect the money to save lives.